alendronate has been researched along with Prostatic Neoplasms in 36 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Prostatic Neoplasms: Tumors or cancer of the PROSTATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with once-weekly 70 mg alendronate significantly improved the BMD at the lumbar spine and femoral neck in patients with prostate cancer with severe osteopenia or osteoporosis and on ADT, and significantly decreased the risk of femoral neck fracture." | 7.75 | Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis. ( Cecchini, L; Encabo, G; Morote, J; Orsola, A; Placer, J; Planas, J; Raventós, C; Salvador, C; Trilla, E, 2009) |
| "1 mg/kg twice weekly or weekly) and dosing along with taxol (10-50 mg/kg/day, twice weekly, or weekly) blocked the growth of PC-3 ML tumors in the bone marrow and soft tissues in a statistically significant manner and improved survival rates significantly (p < 0." | 5.29 | Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice. ( Stearns, ME; Wang, M, 1996) |
| "No BMD test or alendronate therapy, a BMD test followed by selective alendronate therapy for patients with osteoporosis, or universal alendronate therapy without a BMD test." | 3.76 | Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. ( Elkin, EB; Girotra, M; Ito, K; Morris, MJ, 2010) |
| "Treatment with once-weekly 70 mg alendronate significantly improved the BMD at the lumbar spine and femoral neck in patients with prostate cancer with severe osteopenia or osteoporosis and on ADT, and significantly decreased the risk of femoral neck fracture." | 3.75 | Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis. ( Cecchini, L; Encabo, G; Morote, J; Orsola, A; Placer, J; Planas, J; Raventós, C; Salvador, C; Trilla, E, 2009) |
| "Androgen-deprivation therapy (ADT) for prostate cancer is associated with bone loss and osteoporotic fractures." | 2.73 | Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. ( Greenspan, SL; Miller, ME; Nelson, JB; Perera, S; Resnick, NM; Trump, DL; Wagner, JM, 2008) |
| "112 men with nonmetastatic prostate cancer receiving ADT." | 2.73 | Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. ( Greenspan, SL; Nelson, JB; Resnick, NM; Trump, DL, 2007) |
| "Ketoconazole (KT) has demonstrated activity in androgen independent prostate cancer (AIPC)." | 2.71 | A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. ( Arlen, P; Chen, CC; Cox, MC; Cremers, S; Dahut, WL; Figg, WD; Gulley, J; Jones, E; Liewehr, DJ; Liu, Y; Parr, A; Steinberg, SM; Yang, X; Zhai, S, 2005) |
| "Treatment with zoledronic acid probably neither reduces nor increases the proportion of participants with pain response when compared to no treatment/placebo (risk ratio (RR) 1." | 2.66 | Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. ( Adams, A; Heidenreich, A; Jakob, T; Kuhr, K; Macherey, S; Monsef, I; Skoetz, N; Tesfamariam, YM, 2020) |
| "Osteoporosis is a complication of androgen deprivation therapy in men with prostate carcinoma." | 2.42 | Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma. ( Smith, MR, 2003) |
| "Oral etidronate has been found to be ineffective in patients with multiple myeloma and prostate carcinoma bone metastases." | 2.41 | Oral bisphosphonates: A review of clinical use in patients with bone metastases. ( Berenson, J; Hortobagyi, G; Lipton, A; Major, PP, 2000) |
| "Ninety-seven prostate cancer patients treated with androgen deprivation therapy, and severe osteopenia or osteoporosis were retrospectively studied." | 1.40 | Bone mass behavior after 1 year of different treatment strategies in prostate cancer patients subjected to androgen deprivation therapy. ( Carles Galceran, J; Celma Domenech, A; Lorente Garcia, D; Morote Robles, J; Placer Santos, J; Planas Morin, J; Regis, L; Salvador Lacambra, C; Trilla Herrera, E, 2014) |
| "Breast or prostate cancer patients were treated with zoledronate." | 1.39 | Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic. ( Fujimoto, Y; Muramatsu, K; Murayama, M; Nakata, E; Nomura, T; Ogane, S; Sekine, R; Shibahara, T; Shibui, T; Uchiyama, T; Watanabe, A; Yakushiji, T; Yamamoto, N, 2013) |
| "Patients with symptoms of osteoporosis, prostate cancer, or breast cancer were surveyed to determine their knowledge of bisphosphonates." | 1.38 | Awareness and education of patients receiving bisphosphonates. ( Bauer, JS; Beck, N; Eitner, S; Kiefer, J; Stockmann, P; Wichmann, M, 2012) |
| " In two trials involving 1189 and 504 women, the incidence of clinical fractures, recorded as simple adverse effects, did not differ significantly between the groups." | 1.37 | Denosumab. Limited efficacy in fracture prevention, too many adverse effects. ( , 2011) |
| "Historical data on 24 patients with prostate cancer who received ADT without bisphosphonate administration were studied as controls (control group)." | 1.35 | Oral bisphosphonate prevents bone loss in androgen deprivation therapy for nonmetastatic prostate cancer. ( Kawahara, T; Kobayashi, T; Kobori, G; Mitsumori, K; Nishizawa, K; Ogura, K, 2008) |
| "Metastatic prostate cancer is associated with a high morbidity and mortality but the spreading mechanisms are still poorly understood." | 1.35 | Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in nude mice. ( Härkönen, PL; Tuomela, JM; Väänänen, K; Valta, MP, 2008) |
| "Sixty-two (52." | 1.33 | Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. ( Broumand, V; Fortin, M; Marx, RE; Sawatari, Y, 2005) |
| "Alendronate pretreatment also inhibited migration, which was partially reversed by geranylgeraniol and trans-trans-farnesol." | 1.31 | Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. ( Härkönen, PL; Lakkakorpi, PT; Väänänen, HK; Virtanen, SS, 2002) |
| "Alendronate failed to inhibit MMP-2 activity directly, but instead appeared to block cellular secretion of MMP-2." | 1.30 | Alendronate blocks TGF-beta1 stimulated collagen 1 degradation by human prostate PC-3 ML cells. ( Stearns, ME, 1998) |
| "Alendronate pretreatment of the SCID mice (0." | 1.30 | Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice. ( Stearns, ME; Wang, M, 1998) |
| "1 mg/kg twice weekly or weekly) and dosing along with taxol (10-50 mg/kg/day, twice weekly, or weekly) blocked the growth of PC-3 ML tumors in the bone marrow and soft tissues in a statistically significant manner and improved survival rates significantly (p < 0." | 1.29 | Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice. ( Stearns, ME; Wang, M, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (16.67) | 18.2507 |
| 2000's | 16 (44.44) | 29.6817 |
| 2010's | 11 (30.56) | 24.3611 |
| 2020's | 3 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Damasco, JA | 1 |
| Yu, G | 1 |
| Kumar, A | 1 |
| Perez, J | 1 |
| Lirag, RCM | 1 |
| Whitley, EM | 1 |
| Lin, SH | 1 |
| Melancon, MP | 1 |
| Jakob, T | 1 |
| Tesfamariam, YM | 1 |
| Macherey, S | 1 |
| Kuhr, K | 1 |
| Adams, A | 1 |
| Monsef, I | 1 |
| Heidenreich, A | 1 |
| Skoetz, N | 1 |
| Long, M | 1 |
| Liu, X | 1 |
| Huang, X | 2 |
| Lu, M | 1 |
| Wu, X | 1 |
| Weng, L | 1 |
| Chen, Q | 1 |
| Wang, X | 1 |
| Zhu, L | 1 |
| Chen, Z | 1 |
| Wu, C | 1 |
| Chen, W | 1 |
| Lin, R | 1 |
| Wu, J | 1 |
| Zhang, X | 1 |
| Nomura, T | 1 |
| Shibahara, T | 1 |
| Uchiyama, T | 1 |
| Yamamoto, N | 1 |
| Shibui, T | 1 |
| Yakushiji, T | 1 |
| Watanabe, A | 1 |
| Muramatsu, K | 1 |
| Ogane, S | 1 |
| Murayama, M | 1 |
| Sekine, R | 1 |
| Nakata, E | 1 |
| Fujimoto, Y | 1 |
| Planas Morin, J | 1 |
| Celma Domenech, A | 1 |
| Placer Santos, J | 1 |
| Trilla Herrera, E | 1 |
| Salvador Lacambra, C | 1 |
| Lorente Garcia, D | 1 |
| Regis, L | 1 |
| Carles Galceran, J | 1 |
| Morote Robles, J | 1 |
| Rogers, M | 1 |
| Kalra, S | 1 |
| Moukharskaya, J | 1 |
| Chakraborty, K | 1 |
| Niyazi, M | 1 |
| Krishnan, K | 1 |
| Lightner, J | 1 |
| Brannon, M | 1 |
| Stone, WL | 1 |
| Palau, VE | 1 |
| Massey, AS | 1 |
| Pentlavalli, S | 1 |
| Cunningham, R | 1 |
| McCrudden, CM | 1 |
| McErlean, EM | 1 |
| Redpath, P | 1 |
| Ali, AA | 1 |
| Annett, S | 1 |
| McBride, JW | 1 |
| McCaffrey, J | 1 |
| Robson, T | 1 |
| Migaud, ME | 1 |
| McCarthy, HO | 1 |
| Kawahara, T | 1 |
| Kobayashi, T | 1 |
| Nishizawa, K | 1 |
| Kobori, G | 1 |
| Mitsumori, K | 1 |
| Ogura, K | 1 |
| Greenspan, SL | 2 |
| Nelson, JB | 2 |
| Trump, DL | 2 |
| Wagner, JM | 1 |
| Miller, ME | 1 |
| Perera, S | 1 |
| Resnick, NM | 2 |
| Aragon-Ching, JB | 1 |
| Ning, YM | 1 |
| Chen, CC | 2 |
| Latham, L | 1 |
| Guadagnini, JP | 1 |
| Gulley, JL | 1 |
| Arlen, PM | 1 |
| Wright, JJ | 1 |
| Parnes, H | 1 |
| Figg, WD | 3 |
| Dahut, WL | 2 |
| Planas, J | 1 |
| Trilla, E | 1 |
| Raventós, C | 1 |
| Cecchini, L | 1 |
| Orsola, A | 1 |
| Salvador, C | 1 |
| Placer, J | 1 |
| Encabo, G | 1 |
| Morote, J | 1 |
| Kuroda, I | 1 |
| Ueno, M | 1 |
| Ito, K | 1 |
| Elkin, EB | 1 |
| Girotra, M | 1 |
| Morris, MJ | 1 |
| Fedele, S | 1 |
| Porter, SR | 1 |
| D'Aiuto, F | 1 |
| Aljohani, S | 1 |
| Vescovi, P | 1 |
| Manfredi, M | 1 |
| Arduino, PG | 1 |
| Broccoletti, R | 1 |
| Musciotto, A | 1 |
| Di Fede, O | 1 |
| Lazarovici, TS | 1 |
| Campisi, G | 1 |
| Yarom, N | 1 |
| Bauer, JS | 1 |
| Beck, N | 1 |
| Kiefer, J | 1 |
| Stockmann, P | 1 |
| Wichmann, M | 1 |
| Eitner, S | 1 |
| Martins, MA | 1 |
| Martins, MD | 1 |
| Lascala, CA | 1 |
| Curi, MM | 1 |
| Migliorati, CA | 1 |
| Tenis, CA | 1 |
| Marques, MM | 1 |
| Klotz, LH | 1 |
| McNeill, IY | 1 |
| Kebabdjian, M | 1 |
| Zhang, L | 1 |
| Chin, JL | 1 |
| Smith, MR | 1 |
| Andela, VB | 1 |
| Hershman, D | 1 |
| Narayanan, R | 1 |
| Liu, Y | 1 |
| Arlen, P | 1 |
| Gulley, J | 1 |
| Steinberg, SM | 1 |
| Liewehr, DJ | 1 |
| Cox, MC | 1 |
| Zhai, S | 1 |
| Cremers, S | 1 |
| Parr, A | 1 |
| Yang, X | 1 |
| Jones, E | 1 |
| Marx, RE | 1 |
| Sawatari, Y | 1 |
| Fortin, M | 1 |
| Broumand, V | 1 |
| Tuomela, JM | 1 |
| Valta, MP | 1 |
| Väänänen, K | 1 |
| Härkönen, PL | 2 |
| Horan, AH | 1 |
| Stearns, ME | 3 |
| Wang, M | 2 |
| Adami, S | 1 |
| Major, PP | 1 |
| Lipton, A | 1 |
| Berenson, J | 1 |
| Hortobagyi, G | 1 |
| Carrasquillo, JA | 1 |
| Whatley, M | 1 |
| Dyer, V | 1 |
| Dahut, W | 1 |
| Virtanen, SS | 1 |
| Väänänen, HK | 1 |
| Lakkakorpi, PT | 1 |
| Nemoto, R | 1 |
| Sato, S | 1 |
| Nishijima, Y | 1 |
| Miyakawa, I | 1 |
| Koiso, K | 1 |
| Harada, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Randomized Study of High-Dose Ketoconazole With or Without Alendronate Sodium in Patients With Androgen-Independent Metastastic Adenocarinoma of the Prostate[NCT00019695] | Phase 2 | 0 participants | Interventional | 1999-03-31 | Terminated | ||
| Atrasentan and Zometa for Men With Androgen Independent Prostate Cancer Metastatic to Bone: A Randomized Pilot Study[NCT00181558] | Phase 2 | 44 participants | Interventional | 2001-12-31 | Completed | ||
| A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men With Prostate Cancer Metastatic to Bone[NCT00079001] | Phase 3 | 645 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| A Randomized, Open Label, Active Controlled Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous Bisphosphonates[NCT00104650] | Phase 2 | 111 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Randomized Placebo-Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone Alone in Patients With Hormone Refractory Metastatic Prostate Cancer and Pain[NCT00003232] | Phase 3 | 227 participants (Actual) | Interventional | 1997-11-24 | Completed | ||
| A Phase III, Multicenter, Randomized, Controlled Study of Maximum Androgen Blockade With vs. Without Zoledronic Acid in Prostatic Cancer Patients With Metastatic Bone Disease[NCT00685646] | Phase 3 | 227 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| A Randomised Phase II Feasibility Study of Docetaxel (Taxotere®) Plus Prednisolone vs. Docetaxel (Taxotere®) Plus Prednisolone Plus Zoledronic Acid (Zometa®) vs. Docetaxel (Taxotere®) Plus Prednisolone Plus Strontium-89 vs. Docetaxel (Taxotere®) Plus Pred[NCT00554918] | Phase 2 | 300 participants (Anticipated) | Interventional | 2005-02-28 | Completed | ||
| A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer[NCT00321620] | Phase 3 | 1,904 participants (Actual) | Interventional | 2006-04-01 | Completed | ||
| A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41[NCT00216060] | Phase 3 | 63 participants (Actual) | Interventional | 2003-10-31 | Terminated (stopped due to Terminated due to low accrual) | ||
| STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial[NCT00268476] | Phase 2/Phase 3 | 11,992 participants (Actual) | Interventional | 2005-07-08 | Active, not recruiting | ||
| Prevention of Osteoporosis in Men With Prostate Cancer[NCT00048841] | Phase 3 | 112 participants | Interventional | 2002-05-31 | Completed | ||
| A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer[NCT00264420] | Phase 1 | 4 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Overall survival (OS) was defined as the time from randomization to death of any cause. Surviving patients were censored at the date of last follow-up. The median OS with 95% CI was estimated using the Kaplan Meier method. (NCT00079001)
Timeframe: Up to 10 years
| Intervention | months (Median) |
|---|---|
| Zoledronic Acid + Androgen Deprivation Therapy | 37.9 |
| Placebo + Androgen Deprivation Therapy | 36.0 |
"Progression Free Survival (PFS) was defined as the time from registration until disease progression or death, whichever occurs first. The median PFS with 95% CI was estimated using the Kaplan-Meier method.~Progression is defined as one or more of the following: new bone metastases, biochemical progression of PSA, treatment with radiation therapy while on treatment." (NCT00079001)
Timeframe: Up to 10 years
| Intervention | months (Median) |
|---|---|
| Zoledronic Acid + Androgen Deprivation Therapy | 10.6 |
| Placebo + Androgen Deprivation Therapy | 9.2 |
Time to first skeletal related event (SRE) was defined as the time from randomization to first skeletal event. Skeletal events are defined as radiation to bone, clinical fracture, surgery to bone and spinal cord compression and death due to prostate cancer. The median with 95% CI was estimated using the Kaplan Meier method. (NCT00079001)
Timeframe: Up to 10 years
| Intervention | months (Median) |
|---|---|
| Zoledronic Acid + Androgen Deprivation Therapy | 31.9 |
| Placebo + Androgen Deprivation Therapy | 28.8 |
Time from the 1st occurrence of uNTx below 50 nmol BCE/mmol (corrected by creatinine) to the 1st occurrence of uNTx above 50 nmol BCE/mmol up to week 25. For participants who remained below 50 nmol BCE/mmol, the time is censored at the time of last evaluation of uNTx up to week 25. (NCT00104650)
Timeframe: Day 1, week 25
| Intervention | Participants (Number) |
|---|---|
| Bisphosphonate IV Q4W | 25 |
| Denosumab 180 mg Q12W | 32 |
| Denosumab 180 mg Q4W | 35 |
Occurrence of hypercalcemia at grade 3 or 4 according to CTCAE v3 criteria (NCT00104650)
Timeframe: Day 1, week 25
| Intervention | Participants (Number) |
|---|---|
| Bisphosphonate IV Q4W | 0 |
| Denosumab 180 mg Q12W | 0 |
| Denosumab 180 mg Q4W | 0 |
Percent change from baseline to week 25 in Type I serum C-Telopeptide (CTX), calculated using ((week 25 value - baseline value) / baseline value ) x 100. (NCT00104650)
Timeframe: Baseline, week 25
| Intervention | Percent change (Mean) |
|---|---|
| Bisphosphonate IV Q4W | -40.68 |
| Denosumab 180 mg Q12W | -76.74 |
| Denosumab 180 mg Q4W | -68.39 |
Percent change from baseline to week 25 urinary N-telopeptide (uNTX) calculated using ((week 25 value - baseline value) / baseline value ) x 100. (NCT00104650)
Timeframe: Baseline, week 25
| Intervention | Percent change (Mean) |
|---|---|
| Bisphosphonate IV Q4W | -32.91 |
| Denosumab 180 mg Q12W | -69.09 |
| Denosumab 180 mg Q4W | -41.68 |
Skeletal Related Event (SRE), defined as >1 of the following: pathological bone fracture, spinal cord compression, surgery or radiation therapy to bone (including the use of radioisotopes). (NCT00104650)
Timeframe: Day 1, week 25
| Intervention | Participants (Number) |
|---|---|
| Bisphosphonate IV Q4W | 6 |
| Denosumab 180 mg Q12W | 4 |
| Denosumab 180 mg Q4W | 2 |
Time from study day 1 to first Skeletal Related Event (SRE), defined as >1 of the following: pathological bone fracture, spinal cord compression, surgery or radiation therapy to bone (including the use of radioisotopes). (NCT00104650)
Timeframe: Day 1, week 25
| Intervention | Participants (Number) |
|---|---|
| Bisphosphonate IV Q4W | 6 |
| Denosumab 180 mg Q12W | 4 |
| Denosumab 180 mg Q4W | 2 |
Kaplan-Meier estimate of the median time from enrollment to the 1st occurrence of uNTx below 50 nmol BCE/mmol (corrected by creatinine) up to week 25. For participants whose uNTx does not go below 50 nM BCE/mM creatinine, the time is censored at time of last evaluation of uNTx by week 25. (NCT00104650)
Timeframe: Day 1, week 25
| Intervention | Days (Median) |
|---|---|
| Bisphosphonate IV Q4W | 65 |
| Denosumab 180 mg Q12W | 9 |
| Denosumab 180 mg Q4W | 10 |
Urinary N-telopeptide (uNTx) corrected by creatinine (uNTx/Cr) < 50 nmol/mmol at week 13. (NCT00104650)
Timeframe: 13 weeks
| Intervention | Participants (Number) |
|---|---|
| Bisphosphonate IV Q4W | 10 |
| Denosumab 180 mg Q12W | 21 |
| Denosumab 180 mg Q4W | 28 |
Urinary N-telopeptide (uNTX) corrected by creatinine < 50 nmol/mmol at week 25. (NCT00104650)
Timeframe: 25 weeks
| Intervention | Participants (Number) |
|---|---|
| Bisphosphonate IV Q4W | 13 |
| Denosumab 180 mg Q12W | 21 |
| Denosumab 180 mg Q4W | 23 |
Time to the first on-study skeletal-related event (SRE) analyzed for non-inferiority. Kaplan-Meier estimates of the median and its dispersion are reported. (NCT00321620)
Timeframe: Up to 40.5 months
| Intervention | Days (Median) |
|---|---|
| Zoledronic Acid | 521.0 |
| Denosumab | 629.0 |
Time to the first on-study skeletal-related event (SRE), analyzed for superiority of denosumab. Kaplan-Meier estimates of the median and its dispersion are reported. (NCT00321620)
Timeframe: Up to 40.5 months
| Intervention | Days (Median) |
|---|---|
| Zoledronic Acid | 521.0 |
| Denosumab | 629.0 |
"Time to the first-and-subsequent on-study skeletal-related event (SRE), analyzed for superiority of denosumab using multiple event analysis, the event must occur at least 21 days after the previous SRE.~This outcome measure utilizes multiple event times, was analyzed based on a proportional mean model, and is therefore more appropriately summarized by the cumulative mean number of events." (NCT00321620)
Timeframe: Up to 40.5 months
| Intervention | Events (Number) |
|---|---|
| Zoledronic Acid | 584 |
| Denosumab | 494 |
Number of participants experiencing a SRE(skeletal-related event) or death occurred, cumulative from each arm ( a daily oral dose of 30 mg risedronate, or placebo) (NCT00216060)
Timeframe: 36 months
| Intervention | participants (Number) |
|---|---|
| Risedronate Arm | 11 |
| Placebo Arm | 13 |
(NCT00216060)
Timeframe: 36 months
| Intervention | percentage of participants (Number) |
|---|---|
| Risedronate Arm | 50 |
| Placebo Arm | 29 |
(NCT00216060)
Timeframe: 36 months
| Intervention | percentage of participants (Number) |
|---|---|
| Risedronate | 72.5 |
| Placebo | 71.5 |
"Urine total DPD median in response to treatment on both study arms at week 24. compare median from baseline and week 24.~Deoxypyridinoline (DPD) is measured in hydrolyzed urine samples using high-performance liquid chromatography technique. After extraction of the cross-links and elimination of the urine impurities by a Bio-Rad SPE cartridge (Bio-Rad Laboratories, Hercules, CA), total DPD is eluted from reverse-phase high-performance liquid chromatography by ion pair chromatography with isocratic elution.~The compounds are detected as a result of their natural fluorescence with a fluorescence detector" (NCT00216060)
Timeframe: 24 weeks
| Intervention | nmol/mmol creatinine (Median) | |
|---|---|---|
| week 24 | baseline | |
| Placebo Arm | 12.62 | 10.12 |
| Risedronate Arm | 6.91 | 8.83 |
Serum BAP median changes between baseline and week 24. The Ostase assays are performed with an access immunoassay system, which is an assay of serum samples that provides a quantitative measurement of bone alkaline phosphatase (BAP). A mouse monoclonal antibody specific to BAP is added to a re-action vessel with paramagnetic particles coated with goat antimouse polyclonalantibody.Calibrators,controls,andsamplescontainingBAP are added to the coated particles and bind to the anti-BAP monoclonal antibody. After the formation of a solid phase/capture antibody/BAP complex, separation in a magnetic field and washing remove materials not bound to the solid phase. A chemiluminescent substrate, LumiPhos 530, is added to the reaction vessel, and light generated by the reaction is measured with a luminometer. The light production is directly proportional to the concentration of BAP in the sample. The amount of analyte in thesample is determined from a stored multipoint calibration curve (NCT00216060)
Timeframe: 24 week
| Intervention | ng/mL (Median) | |
|---|---|---|
| 24 week | baseline | |
| Placebo Arm | 13.16 | 19.50 |
| Risedronate Arm | 9.5 | 20.95 |
Serum Osteocalcin (OC) medians between baseline and 24 weeks areperformed with the Elecsys 2010 automated analyzer, which uses an electrochemiluminescence immunoassay technique for the in vitro quantitative determination of serum total osteocalcin in humanserum. The assay uses a sandwich test principle in which afirst biotinylated monoclonal antibody recognizing N-MID osteocalcin and a second monoclonal antibody against N-MID osteocalcin labeled with ruthenium are incubated with 20mL of serum. After a first incubation, streptavidin-coated microparticles are added for a second incubation, and the complex becomes bound to the solid phase by interaction of biotin and streptavidin.These microparticles are then magnetically captured onto the surface of an electrode. Application of a voltage on this electrode induces chemiluminescent emission, which is measured by a photomultiplierand compared with a calibration curve that is generated in aninstrument-specific manner by 2-point calibration. (NCT00216060)
Timeframe: 24 week
| Intervention | ug/L (Median) | |
|---|---|---|
| at 24 week | baseline | |
| Placebo Arm | 27.35 | 18.24 |
| Risedronate Arm | 11.88 | 20.08 |
"Urine N-telopeptide (NTX) median changes between baseline and week 24. The assays are performed with the NTx Reagent Pack kit from Ortho-Clinical Diagnostics (Ortho-Clinical Diagnostics/Johnson & Johnson, Amersham, UK), which is a kit designed for the quantitative determination of N-terminal telopeptide (NTx) in human urine on the automated Vitros Immunodiagnostic System ECi (Ortho-Clinical Diagnostics/Johnson & Johnson, Amersham, UK). A competitive immunoassay technique is used. This depends on competition between NTx present in the sample and a synthetic NTx peptide coated on the wells for binding by a horseradish peroxidase (HRP)-labeled antibody conjugate (mouse monoclonal anti-NTx). The conjugate is captured by the peptide coated on the wells; unbound materials are removed by washing.~The bound HRP conjugate is measured by a luminescent reaction." (NCT00216060)
Timeframe: 24 week
| Intervention | nmol BCE/mmol creatinine (Median) | |
|---|---|---|
| at 24 week | baseline | |
| Placebo Arm | 62.95 | 48.08 |
| Risedronate Arm | 20.63 | 41.33 |
7 reviews available for alendronate and Prostatic Neoplasms
| Article | Year |
|---|---|
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Effect of Diphosphonates on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer.
Topics: Absorptiometry, Photon; Alendronate; Androgen Antagonists; Bone Density; Bone Density Conservation A | 2018 |
[Biochemical markers of bone turnover. New aspect. Bone metabolic markers in prostatic carcinoma].
Topics: Alendronate; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Density; Bone Density Conserva | 2009 |
Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma.
Topics: Absorptiometry, Photon; Alendronate; Androgen Antagonists; Anilides; Bone Density; Calcium; Gonadotr | 2003 |
Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer.
Topics: Absorptiometry, Photon; Alendronate; Antineoplastic Agents; Bone Density; Bone Density Conservation | 2004 |
Bisphosphonates in prostate carcinoma.
Topics: Alendronate; Biomarkers; Bone Diseases; Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; C | 1997 |
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasm | 2000 |
5 trials available for alendronate and Prostatic Neoplasms
| Article | Year |
|---|---|
Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy.
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Double-Blin | 2008 |
Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.
Topics: Adult; Aged; Alendronate; Angiogenesis Inhibitors; Diphosphonates; Humans; Ibandronic Acid; Incidenc | 2009 |
A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leupr
Topics: Absorptiometry, Photon; Administration, Oral; Aged; Aged, 80 and over; Alendronate; Alkaline Phospha | 2013 |
A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases.
Topics: Aged; Alendronate; Bone Neoplasms; Drug Therapy, Combination; Humans; Ketoconazole; Male; Middle Age | 2005 |
Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Androgen Antagonists; Biomarkers; Bone Density; Bone De | 2007 |
24 other studies available for alendronate and Prostatic Neoplasms
| Article | Year |
|---|---|
Alendronate conjugate for targeted delivery to bone-forming prostate cancer.
Topics: Alendronate; Animals; Bone Neoplasms; Cell Line, Tumor; Endothelial Cells; Humans; Hydroxyapatites; | 2023 |
Alendronate-functionalized hypoxia-responsive polymeric micelles for targeted therapy of bone metastatic prostate cancer.
Topics: Alendronate; Cell Line, Tumor; Drug Carriers; Humans; Hydrogen-Ion Concentration; Hypoxia; Male; Mic | 2021 |
Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic.
Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial | 2013 |
Bone mass behavior after 1 year of different treatment strategies in prostate cancer patients subjected to androgen deprivation therapy.
Topics: Aged; Aged, 80 and over; Alendronate; Androgen Antagonists; Anilides; Antibodies, Monoclonal, Humani | 2014 |
Synergistic growth inhibition of PC3 prostate cancer cells with low-dose combinations of simvastatin and alendronate.
Topics: Alendronate; Apoptosis; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Gene Exp | 2015 |
Potentiating the Anticancer Properties of Bisphosphonates by Nanocomplexation with the Cationic Amphipathic Peptide, RALA.
Topics: Alendronate; Animals; Antineoplastic Agents; Bone Density Conservation Agents; Cell Line, Tumor; Cel | 2016 |
Oral bisphosphonate prevents bone loss in androgen deprivation therapy for nonmetastatic prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Androgen Antagonists; Antineoplastic Age | 2008 |
Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
Topics: Absorptiometry, Photon; Aged; Alendronate; Androgen Antagonists; Bone Density; Bone Density Conserva | 2009 |
Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer.
Topics: Aged; Aged, 80 and over; Alendronate; Androgen Antagonists; Antineoplastic Agents; Bone Density; Bon | 2010 |
Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Breast Neoplasms; Dip | 2010 |
Awareness and education of patients receiving bisphosphonates.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Arthralgia; Bisphosphonate-Associated Os | 2012 |
Denosumab. Limited efficacy in fracture prevention, too many adverse effects.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Ag | 2011 |
Association of laser phototherapy with PRP improves healing of bisphosphonate-related osteonecrosis of the jaws in cancer patients: a preliminary study.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bon | 2012 |
Correspondence Re S. S. Virtanen et al., Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 2002;62:2708-14. Re K. Sawada et al., Alendronate inhibits lysophosphatidic acid-induced migration of huma
Topics: Alendronate; Humans; Male; Mevalonic Acid; Neoplasm Invasiveness; Prostatic Neoplasms | 2004 |
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
Topics: Abscess; Alendronate; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breas | 2005 |
Summaries for patients. Preventing bone loss in men with prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Androgen Antagonists; Biomarkers; Bone Density; Bone De | 2007 |
Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in nude mice.
Topics: Adenocarcinoma; Alendronate; Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Divi | 2008 |
Re: Osteoporosis as a complication of orchiectomy in 2 elderly men with prostatic cancer.
Topics: Aged; Alendronate; Animals; Antineoplastic Agents, Hormonal; Diphosphonates; Humans; Leuprolide; Mal | 1996 |
Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice.
Topics: Alendronate; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protoc | 1996 |
Alendronate blocks TGF-beta1 stimulated collagen 1 degradation by human prostate PC-3 ML cells.
Topics: Alendronate; Antineoplastic Agents; Bone Neoplasms; Collagen; Gelatinases; Humans; Hydroxyproline; M | 1998 |
Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice.
Topics: Alendronate; Animals; Bone Neoplasms; Collagen; Collagenases; Enzyme-Linked Immunosorbent Assay; Gel | 1998 |
Alendronate does not interfere with 99mTc-methylene diphosphonate bone scanning.
Topics: Aged; Alendronate; Bone Neoplasms; Humans; Male; Middle Aged; Prospective Studies; Prostatic Neoplas | 2001 |
Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway.
Topics: Alendronate; Antimetabolites; Bone Neoplasms; Cell Movement; Clodronic Acid; Dose-Response Relations | 2002 |
Effects of a new bisphosphonate (AHBuBP) on osteolysis induced by human prostate cancer cells in nude mice.
Topics: Adenocarcinoma; Alendronate; Animals; Diphosphonates; Etidronic Acid; Humans; Male; Mice; Mice, Nude | 1990 |